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ABSTRACT 
The ritterazine and cephalostatin natural products have biological activities 
and structures that are interesting to synthetic organic chemists. These products have 
been found to exhibit significant cytotoxicity against P388 murine leukemia cells, and 
therefore have the potential to be used as anticancer drugs. The ritterazines and 
cephalostatins are steroidal dimers joined by a central pyrazine ring. Given that the 
steroid halves are unsymmetrical and highly oxygenated, there are several challenges 
in synthesizing these compounds in an organic laboratory. 
Ritterazine B is the most potent derivative in the ritterazine family. Its 
biological activity is comparable to drugs that are being used to treat cancer today. 
For this reason, and the fact that there are no reported syntheses of ritterazine B to 
date, our lab set out to synthesize this natural product. 
Herein, efforts toward the synthesis of the western fragment of ritterazine B 
are described. Two different routes are explored to access a common intermediate. An 
alkyne conjugate addition reaction was initially investigated due to the success of this 
key reaction in the synthesis of the eastern fragment. However, it has been found that 
a propargylation reaction has greater reactivity and yields, and has the potential to 
reduce the step count of the synthesis of the western fragment of ritterazine B.  
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Chapter 1 
Background Information on Ritterazines and Cephalostatins 
 
1.1 ISOLATION AND BIOLOGICAL DATA 
 Ritterazines A through Z are natural products that were isolated from the 
Japanese marine tunicate Ritterella tokioka by Fusetani et al, collected at depths of 3–
5 m off the Izu Peninsula, 100 km southwest of Tokyo.1 Tunicates such as Ritterella 
tokioka have found to be a significant source of cytotoxic compounds, including the 
didemnins, the ecteinascidins, and the patellazoles.1 Upon isolation via lipophilic 
extraction, the extracts were found to exhibit potent activity against P388 murine 
leukemia cells.1d Structurally, ritterazines are dimeric steroidal alkaloids strongly 
resembling the structures of the cephalostatins.1 However, the cephalostatins were 
isolated from the East African hemichordate Cephalodiscus gilchristi in the Indian 
Ocean, hundreds of miles away from the Izu Peninsula.1 Although these natural 
products come from different parts of the world, their structure and biological activity 
is very similar.1  
 Ritterazine B (Figure 1a) was isolated by Fusetani et al. in 1995, and its 
structure was found to strongly resemble the previously isolated ritterazine A (Figure 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!!!!!!!!!!
1 a) Fusetani #1 b) Fusetani #2 c) Fusetani #3 d) Fusetani #4 
!
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1b).1 The UV spectrum of ritterazine B contained a peak at λmax 288 nm, which was 
also found in the spectrum of ritterazine A, indicating that both of these structures 
include a pyrazine ring.1b This pyrazine ring joins the two steroidal moieties, 
facilitating deconstruction of the ritterazine structures into the western and eastern 
fragments. The western half of ritterazine B was determined to possess the same 
connectivity and stereochemistry as that of ritterazine A. This includes a C14’–C15’ 
unsaturation in the D’ ring, hydroxyl groups at C7’, C12’, and C17’, and a 5/6 
spiroketal system with the E’/F’ rings. The eastern half of ritterazine B is slightly less 
oxidized, containing a hydroxyl group at C12, and a 5/5 spiroketal.  
 
Figure 1. (a) Structure of western and eastern fragments of ritterazine B with 
atom labels. (b) Structure of ritterazine A with highlighted differences from 
ritterazine B. 
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Ritterazine B is the most potent of the ritterazine derivatives isolated to date. 
Comparison of the various ritterazine structures can provide insight into the structure-
activity relationships of ritterazine B that are important for biological activity. Table 
1 shows the cytotoxicity against P388 murine leukemia cells for all ritterazine 
derivatives. Ritterazines F and G (Figure 2) are the two most potent compounds after 
ritterazine B, and, unsurprisingly, their structures are very similar to ritterazine B. 
Ritterazine F has the same structure as ritterazine B, except it contains the opposite 
stereochemistry of the 5/5 spiroketal at C22. Ritterazine G has the same structure as 
ritterazine B, except that it contains D ring unsaturation.  
Ritterazines A, E, and Y (Figures 1c and 2, respectively) are also extremely 
potent compounds. The western fragments of ritterazines A and E are the same as 
ritterazines B, F, and G, so therefore, the structural components of the western half 
must be essential for potent biological activity. However, the structures of ritterazines 
A and E are distinguished by eastern fragments with rearranged steroid skeletons in 
which the C and D rings are joined as a 5/5 spirocycle. Lastly, ritterazine Y (Figure 
2) exhibits the same cytotoxicity as ritterazines A and E, however the structure of 
ritterazine Y lacks the rearranged steroid. The eastern half is the same as ritterazine F, 
which was shown not to decrease cytotoxicity substantially. However, the decrease in 
activity from ritterazine F to ritterazine Y comes from the loss of hydroxyl groups at 
C7’ and C17’, and therefore indicating that these functional groups increase 
cytotoxicity.  
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Table 1. Cytotoxic activity of 26 ritterazine derivatives against P388 murine 
leukemia cells (IC50, ng/mL). 
 
 
Figure 2. Structures of ritterazines F, G, E, and Y with highlighted differences 
from ritterazine B.  
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 The related natural product cephalostatin 1 (Figure 3) also contains the 
steroidal dimer joined by a pyrazine ring, however there are some significant 
structural differences. The eastern half of cephalostatin 1 resembles the eastern 
fragment of ritterazine B, except that cephalostatin 1 possesses an unsaturated D ring, 
and the opposite stereochemistry of the 5/5 spiroketal at C22. In addition, 
cephalostatin 1 is further functionalized with hydroxyl groups at C17, C23, and C27. 
The western half of cephalostatin 1 differs more significantly from the corresponding 
ritterazine B fragment. Most strikingly, D’ and E’ rings are fused at C17’ and C13’, 
and the E’ and F’ rings comprise a 6/5 spirocyclic system.  
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Figure 3. Structure of cephalostatin 1 with highlighted differences from 
ritterazine B. 
 
 
 Cephalostatin 1 has more potent biological activity compared to ritterazine B, 
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compounds is oxysterol binding protein (OSBP), and has demonstrated that 
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and ritterazine B inhibit the biosynthesis of sphingomyelin.5 Although these 
experiments have produced interesting results, there are still more questions to be 
answered, and how these natural products bind to OSBP is unknown. 
 
1.2 PRIOR SYNTHETIC STUDIES 
 Shair et. al. reported syntheses of the eastern fragments of ritterazines B, F, 
and G.3 Beginning with the commercially available steroid, hecogenin acetate (1), 
Norrish type I photolytic cleavage of the C12–C13 bond provides aldehyde 2 
(Scheme 1), which, when treated with BF3•OEt2, undergoes an ene reaction to reclose 
the six-membered C ring and produce 3. 3 A three-step procedure involving oxidation 
to the ketone, diastereoselective reduction to the correctly configured alcohol at C12, 
and subsequent protection delivers steroid 4.  
 
Scheme 1. Initial steps in Shair’s syntheses of ritterazines B, F, and G eastern 
halves. 
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Shair then implements several steps to convert the 5/6 spiroketal of 4 to the 
desired 5/5 system found in ritterazine G. Reductive opening of the acetal provides 
primary alcohol 5, which is subjected to selenation/oxidation following the Grieco 
protocol to provide alkene 6. Oxymercuration/demercuration of 6 delivers tertiary 
alcohol 7, which is subjected to a Suárez iodine(III)-mediated oxidative ring closure 
to give the required 5/5 spiroketal. The Suárez reaction produces a 2.5:1 mixture of 
diastereomers, slightly favoring the desired stereochemistry. After isolating the major 
diastereomer, Shair uses a two-step procedure to complete the synthesis of the eastern 
fragment of ritterazine B (9). Compound 8 was subjected to hydrogenation with Pt/C 
in ethanol, and acetyl deprotection to yield the eastern half of ritterazine B (9) in 33% 
overall yield and 11 steps from hecogenin acetate.3 
 
Scheme 2. Completion of Shair’s syntheses of ritterazines G and B eastern 
fragments. 
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As mentioned previously, the eastern half of ritterazine F has the opposite 
stereochemistry to ritterazine B at the 5/5 spiroketal, as found in the minor product 
(10) of the Suárez oxidative cyclization. Shair’s efforts to reduce the double bond of 
10 revealed that the stereochemistry of the spiroketal equilibrates in ethanol, leading 
to a mixture of products favoring ritterazine G and B (Scheme 3).3 This result 
indicated that the stereochemistry of the 5/5 spiroketal in ritterazines G and B is the 
thermodynamic configuration.3 In order to form the contra-thermodynamic spiroketal 
of ritterazine F, Shair hydrogenates compound 8 in acetic acid. This reaction produces 
a mixture of ketal 12 (21% yield), as well as ring opened diastereomers 13 and 14 
(Scheme 4). Upon Suárez oxidation of 13, the desired ritterazine F eastern fragment 
is produced in 25% yield, due to some equilibration of the ketal to compound 9 under 
the reaction conditions.  
 
Scheme 3. Shair’s attempted hydrogenation to form ritterazine F eastern half. 
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Scheme 4. Shair’s endgame for the synthesis of ritterazine F eastern fragment. 
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employs an unusual allylic oxidation with 4-phenyl-1,2,4-triazoline-3,5-dione 
(PTAD), which proceeds through an ene reaction to selectively functionalize the C18 
methyl group, forming a 7-membered hemiaminal.2 Elaboration over five steps 
delivers aldehyde 17, which is treated with BF3•OEt2 to close the C ring and yield 
compound 18. This transformation successfully employs the C14–C15 olefin, which 
is the desired position for cephalostatin 1. 
 The final major transformation involves rearrangement of the spiroketal. This 
requires eight steps and involves oxidative scission of the C20–C22 bond to provide 
ketone 19. Intramolecular aldol reaction of 19 produces enal 20, which is 
homologated to form tertiary alcohol 21. The spiroketal in the western fragment of 
cephalostatin 1 was proposed to be in the thermodynamically stable configuration, 
and it was predicted that treatment of 21 in mild acid would produce the desired 
spiroketal.2 However, this was not the case, and Shair found that the undesired 
stereoisomer was formed. This was surprising given that the correct stereoisomer was 
produced by Fuchs et al. in a similar transformation, although Fuchs’ substrate lacked 
the D-ring unsaturation.2, In order to resolve this outcome, Shair employed a two-step 
bromoetherification/reductive debromination sequence. Following 
bromoetherification of 21 with PhSeBr, compound 22 was subjected to 
debromination, and then epimerization of the spiroketal with acid to yield the western 
half of cephalostatin 1. 
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Scheme 5. Shair’s synthesis of the western fragment of cephalostatin 1 from 
commercially available hecogenin acetate. 
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 Shair’s synthesis of the eastern fragment of cephalostatin 1 begins with 
commercially available trans-androsterone (24). In order to oxidize at C12, Shair 
employs methodology developed by Shönecker et al. that involves condensation of 24 
with 2-(aminomethyl)pyridine in catalytic acid, followed by oxidation with 
stoichiometric Cu(OTf)2 in the presence of molecular oxygen to arrive at diol 25.2,7 
This second step is rather low yielding (25% yield), and presents the opportunity to 
develop an improved method for C12 oxidation in the synthesis of ritterazine B. 
Acetylation of diol 25, followed by conversion to the corresponding vinyl triflate, 
provides 26. This is cross-coupled with a functionalized alkyne fragment using a Pd-
catalyzed Sonogashira coupling to produce 27 in 94% yield.  
Elaboration of 27 through a three-step sequence provides trans-diol 28, which 
undergoes a Au(I)-catalyzed 5-endo-dig cyclization to produce 29 in 88% yield. To 
prepare the precursor for the key spiroketalization, intermediate 29 undergoes 
Simmons–Smith cyclopropanation, and deprotection of the TMS alcohol to provide 
30. The spiroketal of the eastern half of cephalostatin 1 is the contra-thermodynamic 
configuration, which required kinetically controlled spiroketalization.2 This was 
achieved under neutral reaction conditions using NBS, which decrease equilibration 
of the spiroketal to yield 31 as the major diastereomer in a 5:1 separable mixture. 
Completion of the synthesis of cephalostatin 1 eastern fragment involved 
debromination, TMS protection of the hindered alcohol, selective deacetylation of the 
C3 alcohol, and oxidation to the ketone. 
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Scheme 6. Shair’s synthesis of the eastern fragment of cephalostatin 1 from 
commercially available trans-androsterone. 
 
 
 In order to join the two western and eastern fragments (23 and 32, 
respectively), Shair adapted methodology from Fuchs et al. for unsymmetrical 
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pyrazine formation.8,9 Fuchs’ initial studies toward the synthesis of cephalostatin 7 led 
to the desired unsymmetrical product, as well as homocoupling from each of the 
coupling partners.8 Heathcock et al. had presented a solution to this problem by 
coupling α-acetoxy ketones with α-amino methoximes (Scheme 7a), however the 
drawback of this methodology is the low yields (29–43% yield).10 Fuchs et al. 
subsequently improved upon this protocol by substituting the α-acetoxy ketone with 
an α-azido ketone (Scheme 7b), which greatly improved yields. In Fuchs’ synthesis 
of 14’α,15’-dihydrocephalostatin 1 analog, he established that the eastern fragment 
was optimal as the α-amino methoxime, and the western fragment as the α-azido 
ketone.8 Therefore, Shair followed this approach to complete the synthesis of 
cephalostatin 1.2,8 
 
Scheme 7. (a) Unsymmetrical pyrazine formation by Heathcock et al. (b) 
Unsymmetrical pyrazine formation by Fuchs et al. 
 
 
 
 The western fragment of cephalostatin 1 (23) was converted to the α-azido 
ketone 33 through a two-step process. First, α-bromination was achieved with 
PhMe3NBr3, and the bromide was then converted to the desired azide using 
tetramethylguanidinium azide and EtNO2. The eastern half (32) was subjected to the 
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the same bromination/azidation sequence, which was then followed by formation of 
the methoxime. Staudinger reduction of the azide moiety to primary amine 33 
enabled coupling of intermediates 33 and 34 in the presence of polyvinylpyridine and 
Bu2SnCl2 to produce compound 35. Completion of the synthesis of cephalostatin 1 
was achieved upon global deprotection of the siloxy groups.  
 
Scheme 8. Completion of Shair’s total synthesis of cephalostatin 1. 
 
O
Me H
Me
H
H
AcO
cephalostatin 1
eastern fragment (32)
O
O O
OTBS
Me
Me OTBDPSTMS
Me H
H
H
O
cephalostatin 1 
western fragment (23)
O
O
Me
O Me
Me
TBDPSO
H
2 steps
Me H
H
H
O
O
O
Me
O Me
Me
TBDPSO
H
33
N3
4 steps
N
Me H
Me
H
H
AcO
O
O O
OTBS
Me
Me OTBDPSTMS
H2N
OMe
34
N
N
O
O
Me H
AcOMe
OTBS
Me
H
H
O
Me
TBDPSO
MeH
H
H
H
OOO
Me
Me
Me
OTBDPS
cephalostatin 1
TMS
33 + 34
polyvinylpyridine,
Bu2SnCl2, benzene,
80 °C TBAF, THF
(47% yield, 2 steps)
35
Chapter 2 – Efforts in Our Laboratory 17 
!
!
!
Chapter 2 
Efforts in Our Laboratory‡ 
 
2.1 RETROSYNTHETIC ANALYSIS 
Given that conditions for pyrazine formation have been established in prior 
synthetic reports by Shair and Fuchs,2,6,8,9 ritterazine B was retrosynthetically 
simplified to the western (36) and eastern (37) fragments (Scheme 9). From here, our 
proposed retrosynthesis involves two key reactions, which can be employed for both 
halves of the natural product. We envision forming the 5/6 spiroketal of the western 
half and the 5/5 spiroketal of the eastern fragment using a metal-catalyzed alkyne 
spiroketalization reaction with intermediates 38 and 39, respectively. These 
compounds can be produced from an alkyne conjugate addition between 40 and 41 
for the western fragment, and between 42 and 43 for the eastern half. It is anticipated 
that for the western fragment, cyclization of the less hindered primary alcohol will 
occur to produce the 5/6 spirocycle. Enones 40 and 42 can be formed from 
commercially available steroid trans-androsterone (24). Specific issues that need to 
be addressed include improving upon existing methods to oxidize the C12 position, 
which is relevant for both halves of ritterazine B. In addition, for the western 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!!!!!!!!!!
‡ Work conducted in collaboration with Anton Dubrovskiy and Arthur Han. 
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fragment, new strategies to oxidize carbons C7 and C17 and install the C14–C15 
olefin are required. 
 
Scheme 9. Retrosynthetic analysis of ritterazine B. 
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2.2 SYNTHESIS OF THE EASTERN FRAGMENT 
Initial studies in our laboratory were conducted by Anton Dubrovskiy and 
focused on the synthesis of the eastern fragment of ritterazine B beginning from 
commercially available trans-androsterone (24). The sequence begins with a 
Mitsunobu reaction between trans-androsterone (24) and 3-iodobenzoic acid to 
provide ester 44 with inversion of stereochemistry at C3 (Scheme 10). Directed C–H 
chlorination following the protocol developed by Davitishvili et al. furnished chloride 
44 in 61% yield over two steps.11 Subsequent elimination of the chloride to yield the 
C9–C11 olefin occurs with concomitant deprotection of the C3 alcohol, which upon 
Wittig olefination with EtPPh3Br produces olefin 45 in 68% yield over two steps. 
Protection of the alcohol as the pivalate ester followed by allylic oxidation with SeO2 
provided the C16–alcohol, which was oxidized with MnO2 to provide enone 46. After 
considerable experimentation, it was determined that addition of the alkynyl 
trifluoroborate salt to enone 46 in the presence of BF3•OEt2 furnished alkyne 47 in 
77% yield.12,13  
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Scheme 10. Initial steps of our synthesis of ritterazine B eastern fragment.  
 
 
 To prepare the spiroketalization precursor, silyl ether 47 was deprotected and 
the ketone was reduced to the desired β-configured alcohol to give diol 48 (Scheme 
11). We were pleased to find that spiroketalization of 48 proceeded smoothly with 
catalytic AuCl to provide 49 with the correct stereochemistry at C20 and C22.14 
Notably, under the reaction conditions, C20 epimerizes to give the correct 
configuration. An allylic oxidation of 49 using catalytic Rh2(cap)4, K2CO3, and TBHP 
under argon or O2 furnished enone 50.15 Hydrogenation of the C9–C11 olefin with 
Pd(OH)2/C produced 51 in 68% yield.  
The final transformation required to complete the synthesis of ritterazine B 
eastern fragment is conversion of the C/D ring juncture from trans to cis. Adapting 
conditions from Shair, Norrish type I fragmentation of the C12–C13 bond and 
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subsequent closure via a BF3•OEt2-mediated ene reaction provided intermediate 52.2 
Correction of the configuration of the C12 hydroxyl was achieved through 
oxidation/reduction. Following acetylation of the free hydroxyl group, hydrogenation 
produced the desired trans junction, completing the synthesis of the eastern fragment 
(54) in 15 steps from trans-androsterone. 
 
Scheme 11. Completion of our synthesis of the eastern fragment of ritterazine B. 
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2.3 SYNTHESIS OF THE WESTERN FRAGMENT 
2.3.1 Plan 1 – Alkyne Conjugate Addition 
 Given our success in preparing the eastern fragment of ritterazine B, my 
objective was to develop a synthesis of western fragment 38. The initial goal was to 
investigate the conjugate addition reaction of alkyne 41, as this is the first key step in 
our retrosynthesis (repeated in Scheme 12). Although alkyne 41 bears an additional 
hydroxyl group compared to the alkyne 43 (see Scheme 9), we anticipated using a 
similar sequence to that employed for the preparation of 47 (see Scheme 10).  
 
Scheme 12. Retrosynthetic analysis of first key reaction of the western fragment. 
 
 
 To this end, the desired alkyne 61 was initially prepared by a route adapted 
from a procedure published by Shair.2 Starting with 3-methyl-3-buten-1-ol (55), 
protection of the alcohol group as the para-methoxy phenol (PMP) ether gave 56 in 
96% yield (Scheme 13). Asymmetric dihydroxylation provided diol 57, and selective 
protection of the primary alcohol as the tert-butyldiphenyl silyl (TBDPS) ether 
provided 58 in 97% yield. Deprotection of the PMP group, and then DMP oxidation 
produced aldehyde 60. Finally, the Ohira-Bestmann reagent was employed to convert 
the aldehyde to the desired alkyne 61 in 70% yield over two steps. 
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Scheme 13. Initial synthesis of alkyne fragment. 
 
 
 The benefit of intermediate 61 is that several protecting group schemes could 
be investigated to find the optimal substrate for the conjugate addition reaction. 
Whereas treatment of 62a (R = MOM) or 62b (R = TES) with n-BuLi, B(OMe)3, then 
KHF2 provided the corresponding trifluoroborates (Table 2, entries 1 and 2), we were 
surprised to find that no reaction occurred under the same conditions with 62c (R = 
TBS). The origin of this difference in reactivity is unclear, however it is possible that 
the increased steric hindrance of TBS is responsible for the lack of reactivity. 
 
Table 2. Initial attempts to form alkynyl trifluoroborate salt. 
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 With trifluoroborates 63a and 63b in hand, the key conjugate addition reaction 
was investigated. Woodward et al. have shown that conjugate additions of alkynyl 
trifluoroborates to enones proceed through a closed transition state (Scheme 14).13  In 
the presence of BF3, the trifluoroborate salt is in equilibrium with the more active 
alkynyl BF2 species, which forms a chair–like closed transition state that facilitates 
alkyne addition in a 1,4 fashion.13 Unfortunately, under the previously optimized 
conditions, treatment of enone 64 with either trifluoroborate salts 63a or 63b gave 
only 1,2–addition product 65a and 65b (Scheme 15). Interestingly, the tertiary 
alcohol in the product was deprotected under the reaction conditions in both cases. A 
possible mechanism to produce 65 involves activation of the ketone with BF3, 
followed by nucleophilic attack of the trifluoroborate salt at the carbonyl carbon.   
 
Scheme 14. Mechanism and transition state of alkyne conjugate addition using 
trifluoroborate salts. 
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Scheme 15. First attempt at conjugate addition. 
 
 
 To determine whether the primary alcohol protecting group exerts any 
influence on the reactivity of the conjugate addition, further alkynyl derivatives were 
prepared. However, the synthesis of the alkyne fragment (shown in Scheme 13) did 
not lend itself to late stage diversification. Therefore, a more rapid and efficient 
synthesis of the alkyne fragment was developed based on a catalytic asymmetric 
reaction reported by Shaus et al. (Scheme 16).16 Beginning with hydroxyacetone (66), 
the free alcohol was protected as the tri-iso-propylsilyl (TIPS) ether (67). Treatment 
of 67 with allenylboronate 68 and catalytic BINOL under microwave irradiation 
produced 69 in 62% yield. This route has proven to be significantly more convenient 
and has greatly improved the synthesis of the alkyne fragment.  
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Scheme 16. Improved synthesis of alkyne fragment. 
 
 
 After protection of the tertiary alcohol of 69 as the TBS ether, this compound 
was subjected to the standard conditions for trifluoroborate formation. Unfortunately, 
no reaction occurred and starting material was recovered (entry 1, Table 3). Attempts 
to change the identity of the tertiary alcohol protecting group of 69 were 
unsuccessful. Therefore, we turned our attention to altering the primary alcohol 
protecting group. Disappointingly, efforts to convert the bis-silyl ethers 70b and 70c 
to their corresponding trifluoroborates were also unsuccessful (entries 2 and 3). 
 
Table 3. Attempts to form the desired trifluoroborate salt.  
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 Concomittant to my own efforts, my co-workers were also preparing alkynyl 
trifluoroborates with varying protecting groups. This collective effort determined that 
alkynyl trifluoroborates 71a and 71b can be prepared, and that these compounds will 
undergo the desired conjugate addition reactions in 25% and 56% yield respectively. 
 
Table 4. Most current results with the conjugate addition reaction.  
 
 
 Future directions of this synthetic route involve applying the alkynyl 
conjugate addition to a fully oxidized western steroid. Most importantly, methods to 
oxidize at C17 following the conjugate addition reaction must be investigated. One 
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74 (Scheme 17). This type of reaction has been developed using a variety of allenyl 
metal species, including tin,17 magnesium,18 lithium,19 titanium,20 boron,21 and zinc,22 
as well as others. Most allenyl metal reagents are unstable, and are therefore 
generated in situ.17a A complicating factor is that these reagents are often in 
equilibrium with the propargylic species, however sufficient research has been done 
to favor the propargylic adduct.17a Although the diastereoselectivity of the 
transformation was initially uncertain, this route is attractive in that the C17 alcohol 
would be installed directly during the propargylation reaction.  
 
Scheme 17. Revised retrosynthesis of intermediate 38 using propargylation. 
 
 
 In order to investigate this reaction, model steroid trans-androsterone (24) was 
oxidized α to the carbonyl using the two-step procedure reported by Ridley et al. 
(Scheme 18).23 Treatment of 24 with isopropenyl acetate and catalytic sulfuric acid at 
reflux produced protected enolate 75, which upon subsequent oxidation with lead(IV) 
acetate provided α-acetoxy ketone 76 in 52% yield (61% yield b.r.s.m.). We were 
pleased to find that exposure of 76 at –78 °C to allenylmagnesium bromide (77), 
generated in situ from propargyl bromide, produced homopropargyl alcohol 78 in 
78% yield. Moreover, alcohol 78 was produced as a single diastereomer.  
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Scheme 18. Initial hit in propargylation studies with model ketone. 
 
 
 Unfortunately, stereochemical analysis by 1D- and 2D-NMR determined that 
78 possesses the incorrect configuration at C17. In an effort to overturn this 
diastereoselectivity, a variety of protecting groups capable of directing delivery of the 
allenyl Grignard were initially pursued. Table 5 shows the results of substrates 
bearing different protecting groups with allenyl Grignard. Unfortunately, treatment of 
the substrates under standard conditions still resulted in allenylation to give the 
undesired propargylation product. 
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Table 5. Reaction of allenyl Grignard with directing protecting groups. 
 
 
Given the lack of success overturning the diastereoselectivity on the β-
disposed C16 hydroxyl, we turned our attention to investigating the propargylation of 
steroids bearing the inverted stereochemistry at position C16. We hypothesized that a 
large sterically bulky protecting group would block the α-face, directing 
propargylation to the β-face. Diol 80 was prepared using a two-step procedure 
developed by Numazawa and Osawa et al. by performing an α-bromination, followed 
by SN2 displacement (Scheme 19).24 After TBS protection to form 81, propargylation 
with allenyl Grignard resulted in a mixture of diastereomers 82/83 2.5:1 d.r. Although 
the major diastereomer 82 is the undesired stereochemistry, formation of the desired 
product 83 was a promising result. 
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Scheme 19. Propargylation with α-configuration at C16. 
 
 
 Reetz et al. have demonstrated that diastereoselectivity of propargylation 
reactions can be influenced by using TiCl4 as an additive.25 It is proposed that TiCl4 
can coordinate to the carbonyl oxygen, as well as oxygen atoms of an ether protecting 
group, and promote propargylation through an open transition state. Inspired by 
Reetz’s findings, compound 84 was prepared and subjected to allenyl Grignard and 
TiCl4 in dichloromethane at –78 °C (Scheme 20). Much to our pleasure, 
homopropargyl alcohol 85 was formed in 77% yield as a single diastereomer, with the 
correct stereochemistry at C17.  
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Scheme 20. Propargylation with TiCl4 to form the desired stereochemistry at 
C17. 
 
 
 Having achieved the desired stereoselectivity, we turned to investigating more 
complex allenyl Grignard reagents. Reaction of steroid 84 with methylated allenyl 
Grignard 86, prepared from 3-bromo-1-butyne, produced a mixture of two 
diastereomers 87 and 88  in 47% and 23% yields, respectively (Scheme 21). These 
two diastereomers arise from the fact that Grignard 86 is racemic; it was anticipated 
that the enantioenriched allene would deliver the desired product with high 
diastereoselectivity. 
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Scheme 21. Initial attempts at propargylation with methylated allenyl Grignard 
86. 
 
 
 To investigate the diastereoselectivity with a chiral allene, a protocol was 
adapted from Marshall et al.26 Beginning with (S)-(–)-butyn-2-ol (89), attempts to 
isolate chiral bromide 90 were unsuccessful due to volatility of the bromide (Scheme 
22). As an alternative intermediate, mesylate 91 was formed as a precursor for the 
chiral allenyl zinc reagent 92. Upon treatment of steroidal ketone 84 with zinc reagent 
92, homopropargyl alcohol 87 was formed as a single diastereomer, and the structure 
of 87 was confirmed via X-ray crystallography (Figure 4) to verify the 
stereochemistry at C20. 
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Scheme 22. Propargylation with chiral allenyl zinc reagent. 
 
 
Figure 4. X-ray structure of alcohol 87. 
 
 
2.4 FUTURE DIRECTIONS 
 The next step in investigating the synthetic utility of the propargylation 
reaction in the total synthesis of ritterazine B would be to incorporate the oxygenated 
aliphatic chain on the alkyne. An efficient method to accomplish this goal involves a 
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reaction developed by Trost et al. that forms chiral propargyl alcohols 95 from 
acetaldehyde (93) and terminal alkynes 94 (Scheme 23a).27 Using our previously 
established conditions to form the protected alkyne fragment 98, the desired chiral 
homopropargyl alcohol 99 can be synthesized in four steps (Scheme 23b).  
 
Scheme 23. (a) Formation of chiral propargyl alcohols by Trost et al. (b) Plan to 
form desired propargyl alcohol using Trost’s method. 
 
 
 
With alcohol 99 in hand, there are two possible conditions for the 
propargylation reaction with steroid 84 that could deliver the desired product. The 
first set of conditions utilizes chiral allenyl zinc mesylate 101, which is formed from 
the corresponding mesylate 100 (Scheme 24a). Treatment of 84 with zinc mesylate 
101 will produce homopropargyl alcohol 102. However, since the yield of the 
propargylation reaction with allenyl zinc 92 (see Scheme 22) was low yielding, either 
optimization of these conditions or investigation of a different metal are required. 
Using the (R,R)-ProPhenol ligand in the Trost reaction with acetaldehyde (93) and 
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alkyne 98 delivers R-alcohol 103, which will undergo an SN2 reaction to form 
bromide 104 as a precursor to the chiral allenyl Grignard 105 (Scheme 24b). 
Treatment of steroid 84 with in situ-generated Grignard 105 should produce the 
desired homopropargyl alcohol 102. 
 
Scheme 24. Plans to produce homopropargyl alcohol 102 (a) using a chiral 
allenyl zinc mesylate or (b) using a chiral allenyl Grignard. 
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 In order to utilize the propargylation reaction in the synthesis of the western 
fragment of ritterazine B, the steroid substrate needs to be oxidized at C7 and C12 
prior to the propargylation reaction. trans-Dehydroandrosterone 103 will be oxidized 
at C12 using Shair’s two-step procedure to provide 104,2 followed by ketone 
protection, oxidation at C7, hydrogenation, and ketone deprotection to deliver 
compound 105 (Scheme 25). To access propargylation substrate 106, intermediate 
105 undergoes α-bromination and SN2 displacement, and treatment of 106 with a 
chiral allene 107 will produce homopropargyl alcohol 108. To install the double bond 
at C14–C15, the tertiary alcohol is protected, C16 MOM ether is deprotected, 
oxidized, and a Mukaiyama reaction will provide enone 109. Reduction at C16 to 
alcohol 110, followed by primary alcohol deprotection and alkyne spiroketalization 
should produce ritterazine B western fragment 111. This substrate can be coupled 
with the eastern half of ritterazine B via pyrazine formation to complete the total 
synthesis of ritterazine B. 
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Scheme 25. Plans to complete the synthesis of ritterazine B western fragment. 
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2.5 EXPERIMENTAL SECTION 
2.5.1 Materials and Methods 
Unless otherwise stated, reactions were performed under a nitrogen 
atmosphere using freshly dried solvents. Tetrahydrofuran (THF), methylene chloride 
(CH2Cl2), acetonitrile (MeCN), dimethylformamide (DMF), and toluene (PhMe) were 
dried by passing through activated alumina columns. Unless otherwise stated, 
chemicals and reagents were used as received. Triethylamine (Et3N) was distilled 
over calcium hydride prior to use. All reactions were monitored by thin-layer 
chromatography using EMD/Merck silica gel 60 F254 pre-coated plates (0.25 mm) 
and were visualized by UV, p-anisaldehyde, or KMnO4 staining. Flash column 
chromatography was performed either as described by Still et al.28 using silica gel 
(particle size 0.032-0.063) purchased from Silicycle or using pre-packaged 
RediSep®Rf columns on a CombiFlash Rf system (Teledyne ISCO Inc.). Optical 
rotations were measured on a Jasco P-2000 polarimeter using a 100 mm path-length 
cell at 589 nm. 1H and 13C NMR spectra were recorded on a Varian 400 MR (at 400 
MHz and 101 MHz, respectively), a Varian Inova 500 (at 500 MHz and 126 MHz, 
respectively), or a Varian Inova 600 (at 600 MHz and 150 MHz, respectively), and 
are reported relative to internal CHCl3 (1H, δ = 7.26), MeCN (1H, δ = 1.94), or 
DMSO (1H, δ = 2.50), and CDCl3 (13C, δ = 77.0), MeCN (13C, δ = 118.26), or DMSO 
(13C, δ = 40.0). Data for 1H NMR spectra are reported as follows: chemical shift (δ 
ppm) (multiplicity, coupling constant (Hz), integration). Multiplicity and qualifier 
abbreviations are as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet, br = broad, app = apparent. IR spectra were recorded on a Perkin Elmer 
Chapter 2 – Efforts in Our Laboratory 40 
Paragon 1000 spectrometer and are reported in frequency of absorption (cm–1). 
HRMS were acquired using an Agilent 6200 Series TOF with an Agilent G1978A 
Multimode source in electrospray ionization (ESI), atmospheric pressure chemical 
ionization (APCI), or mixed (MM) ionization mode.  
 
2.5.2 Prepartive Procedures and Spectoscopic Data 
 
1-methoxy-4-((3-methylbut-3-en-1-yl)oxy)benzene (56) 
A flask was charged with 4-methoxyphenol (2.54 g, 20.5 mmol) and PPh3 
(2.33 g, 8.87 mmol), and then THF (23 mL) was added. The addition of alcohol 55 
(0.588 g, 6.82 mmol) was followed by the addition of diisopropyl azodicarboxylate 
(1.75 mL, 8.87 mmol), and the reaction was heated to a reflux for 3.5 h. The reaction 
was cooled to room temperature, and THF was removed under pressure. The resulting 
residue was loaded unto a column and purified by column chromatography (5% 
EtOAc/Hex) to produce 56 (1.26 g, 96% yield). 
 
 
(S)-4-(4-methoxyphenoxy)-2-methylbutane-1,2-diol (57) 
 K2CO3 (3.49 g, 25.2 mmol), K3Fe(CN)6 (8.31 g, 25.2 mmol), K2OsO4•2H2O 
(12.4 mg, 0.0336 mmol), and (DHQ)2PHAL (65.5 mg, 0.0841 mmol) were added all 
at once to a solution of olefin 56 (1.62 g, 8.41 mmol) in t-BuOH (45 mL) and H2O 
OH
Me
OPMP
Me
55 56
OPMP
HO
HO Me
57
OPMP
Me
56
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(45 mL) at 0 °C. After 5 h at room temperature, Na2SO3 (12.7 g, 100 mmol) was 
added and the mixture was stirred for 5 min. Minimal water was added and the 
aqueous layer was extracted from EtOAc four times. The combined organics were 
washed with brine, and dried over MgSO4. The crude was purified by column 
chromatography (20%→50% EtOAc/Hex) to give 57 (1.68 g, 88% yield). 
 
 
(S)-1-((tert-butyldiphenylsilyl)oxy)-4-(4-methoxyphenoxy)-2-methylbutan-2-ol 
(58) 
 Imidazole (0.247 g, 3.63 mmol), followed by TBDPSCl (0.69 mL, 2.66 
mmol), was added to a solution of diol 57 (0.548 g, 2.42 mmol) in DMF (2.7 mL). 
After stirring overnight at room temperature, the reaction was quenched with sat. 
NH4Cl and extracted with ether three times. The combined organic layers were 
washed with water, then brine, and then dried over MgSO4. The crude product was 
purified via column chromatography (15%→40% EtOAc/Hex) to give 58 (1.09 g, 
97% yield). 
 
 
(S)-4-((tert-butyldiphenylsilyl)oxy)-3-methylbutane-1,3-diol (59) 
 A solution of CAN (2.61 g, 4.76 mmol) in water (11 mL) was added dropwise 
via an addition funnel to a solution of alcohol 58 (1.09 g, 2.36 mmol) in acetonitrile 
(9.5 mL) at 0 °C. After 15 min, EtOAc and water was added and the layers were 
OPMP
TBDPSO
HO Me
58
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HO
HO Me
57
OH
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HO Me
59
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separated. Aqueous was extracted from EtOAc twice more, and then the combined 
organics were washed with water, then brine, and then dried over MgSO4. The crude 
was purified via column chromatography (eluting with CH2Cl2 to remove impurities, 
and then EtOAc to elute product) to give 59 (0.829 g, 98% yield). 
 
 
(S)-4-((tert-butyldiphenylsilyl)oxy)-3-hydroxy-3-methylbutanal (60) 
Dess-Martin periodinane (48.8 mg, 0.115 mmol) was added to a solution of 
diol 59 (27.5 mg, 0.0767 mmol) in dichloromethane (0.5 mL) and this was stirred 
overnight. The reaction was quenched with a 1:1 mixture of sat. NaHCO3/1.5 M 
Na2S2O3 and the aqueous layer was extracted from Et2O three times. The combined 
organic layers were washed with brine and dried over MgSO4, and crude aldehyde 60 
was used in the next step without purification. 1H NMR (500 MHz, CDCl3) δ 9.87 (t, 
J = 2.4 Hz, 1H), 7.68 – 7.61 (m, 4H), 7.48 – 7.37 (m, 6H), 3.53 (d, J = 1.3 Hz, 2H), 
2.88 (s, 1H), 2.73 (dd, J = 15.6, 2.3 Hz, 1H), 2.49 (dd, J = 15.7, 2.6 Hz, 1H), 1.26 (s, 
3H), 1.09 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 202.1, 135.6, 132.8, 123.0, 127.9, 
72.2, 70.9, 51.6, 26.9, 24.3, 19.3; IR (NaCl/thin film): 3453, 3071, 3047, 2959, 2931, 
2888, 2858, 2739, 1720, 1472, 1461, 1428, 1391, 1362, 1188, 1155, 1112, 824, 741 
cm–1; HRMS (Multimode-ESI/APCI) calc’d for C21H28O3Si [M–H] – 355.1735, found 
355.1736. 
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(S)-1-((tert-butyldiphenylsilyl)oxy)-2-methylpent-4-yn-2-ol (61) 
K2CO3 (16.6 mg, 0.120 mmol), followed by Ohira–Bestmann reagent (13.8 
mg, 0.0719 mmol), was added to a solution of crude aldehyde 60 (25.7 mg, 0.0599 
mmol) in MeOH (1 mL), and this was stirred at room temperature overnight. The 
reaction was quenched with sat. NaHCO3 and diluted with Et2O. The aqueous layer 
was extracted from Et2O three times, and then the combined organic layers were 
washed with brine and dried over MgSO4. The crude product was purified by column 
chromatography (5% EtOAc/Hex) to provide alkyne 61 (18.9 mg, 70% yield over two 
steps). 1H NMR (500 MHz, CDCl3) δ 7.76 – 7.66 (m, 4H), 7.48 – 7.36 (m, 6H), 3.67 
(d, J = 9.7 Hz, 1H), 3.54 (d, J = 9.8 Hz, 1H), 2.59 (s, 1H), 2.58 – 2.46 (m, 2H), 2.01 
(t, J = 2.7 Hz, 1H), 1.28 (s, 3H), 1.10 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 135.6, 
129.8, 127.8, 80.8, 72.2, 70.6, 69.5, 29.1, 26.6, 23.0, 19.3; IR (NaCl/thin film): 3561, 
3452, 3071, 3050, 2998, 2959, 2931, 2892, 2858, 1590, 1487, 1472, 1464, 1428, 
1391, 1362, 1188, 1152, 1113, 1090, 998, 908, 824, 742 cm–1; HRMS (Multimode-
ESI/APCI) calc’d for C22H28O2Si [M•]+ 352.1853, found 352.1832. 
 
 
(S)-5,9,9-trimethyl-8,8-diphenyl-5-(prop-2-yn-1-yl)-2,4,7-trioxa-8-siladecane 
(62a) 
Bu4NI (3.1 mg, 0.00834 mmol), followed by N,N-diisopropylethylamine (0.02 
mL, 0.125 mmol) was added to a solution of alkyne 61 (14.7 mg, 0.0417 mmol) in 
O
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THF (0.5 mL). After dropwise addition of chloromethyl methyl ether (MOMCl, 0.01 
mL, 0.167 mmol), the reaction was heated to 80 °C and stirred for 2 h. Upon cooling 
to room temperature, the reaction was quenched with water and the aqueous layer was 
extracted from Et2O three times. The combined organic layers were washed with 
brine and dried over MgSO4. The crude product was purified by column 
chromatography (5% EtOAc/Hex) to provide 62a (15.1 mg, 91% yield). 1H NMR 
(500 MHz, CDCl3) δ 7.69 (ddt, J = 7.9, 6.2, 1.7 Hz, 4H), 7.46 – 7.35 (m, 6H), 4.81 – 
4.76 (m, 2H), 3.73 (d, J = 10.2 Hz, 1H), 3.60 (d, J = 10.2 Hz, 1H), 3.35 (s, 3H), 2.66 – 
2.55 (m, 2H), 1.98 (t, J = 2.7 Hz, 1H), 1.35 (s, 3H), 1.08 (s, 9H); 13C NMR (126 
MHz, CDCl3) δ 135.7, 135.5, 129.7, 127.6, 91.6, 81.1, 77.9, 70.2, 68.3, 55.4, 27.4, 
26.9, 20.8, 19.3; IR (NaCl/thin film): 3309, 3071, 3050, 2932, 2891, 2858, 1472, 
1428, 1390, 1362, 1189, 1144, 1112, 1040, 1007, 996, 918, 824, 739, 702 cm–1; 
HRMS (Multimode-ESI/APCI) calc’d for C24H32O3Si [M+H]+ 397.2193, found 
397.2182. 
 
 
(S)-8,8-diethyl-2,2,6-trimethyl-3,3-diphenyl-6-(prop-2-yn-1-yl)-4,7-dioxa-3,8-
disiladecane (62b) 
DMAP (7.6 mg, 0.0618 mmol) and imidazole (16.8 mg, 0.247 mmol) were 
added to a solution of alkyne 61 (21.8 mg, 0.0618 mmol) in DMF (0.3 mL). 
Chlorotriethylsilane (TESCl, 0.03 mL, 0.185 mmol) was added and the reaction was 
heated to 40 °C for 4 h. Upon cooling to room temperature, DMF was extracted from 
hexanes three times and the combined hexane layers were washed with water, then 
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brine, and dried over MgSO4. The crude product was purified by column 
chromatography (5% EtOAc/Hex) to provide alkyne 62b (18.2 mg, 63% yield, 85% 
yield b.r.s.m.). [α]  = +4 ° (c = 0.455, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.73 
– 7.67 (m, 4H), 7.45 – 7.35 (m, 6H), 3.58 (d, J = 9.6 Hz, 1H), 3.46 (d, J = 9.6 Hz, 
1H), 2.51 (ddd, J = 72.1, 16.4, 2.7 Hz, 2H), 1.95 (t, J = 2.7 Hz, 1H), 1.31 (s, 3H), 1.06 
(s, 9H), 0.90 (t, J = 7.9 Hz, 9H), 0.55 (qd, J = 7.9, 1.3 Hz, 6H); 13C NMR (126 MHz, 
CDCl3) δ135.7, 133.6, 129.6, 127.6, 81.9, 75.3, 70.3, 67.0, 30.0, 26.9, 24.6, 19.3, 
6.97, 6.74; IR (NaCl/thin film): 3311, 3071, 3050, 2955, 2932, 2875, 2858, 1472, 
1459, 1428, 1239, 1195, 1160, 1112, 1030, 1016, 1009, 821, 740 cm–1; HRMS 
(Multimode-ESI/APCI) calc’d for C28H42O2Si2 [M+H]+ 467.2796, found 467.2705. 
 
 
(S)-2,2,3,3,5,9,9-heptamethyl-8,8-diphenyl-5-(prop-2-yn-1-yl)-4,7-dioxa-3,8-
disiladecane (62c) 
TBSCl (11.5 mg, 0.0766 mmol), imidazole (5.2 mg, 0.0766 mmol) and 61 
(13.5 mg, 0.0383 mmol) were heated neat to 120 °C overnight. The reaction was 
quenched with water and diluted with dichloromethane, and the aqueous layer was 
extracted from dichloromethane three times. The combined organic layers were 
washed with brine and dried over MgSO4. The crude product was purified by flash 
chromatography (Hex→5% EtOAc/Hex) to give 62c (15.9 mg, 89% yield). [α]  = 
+2 ° (c = 0.795, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.81 – 7.71 (m, 4H), 7.45 – 
7.31 (m, 6H), 3.50 (d, J = 9.5 Hz, 1H), 3.34 (d, J = 9.5 Hz, 1H), 2.45 (dd, J = 16.4, 
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2.7 Hz, 1H), 2.31 (dd, J = 16.4, 2.7 Hz, 1H), 1.94 (t, J = 2.7 Hz, 1H), 1.11 (s, 3H), 
1.03 (s, 9H), 0.85 (s, 9H), -0.03 (s, 3H), -0.05 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 
136.2, 135.6, 129.4, 127.4, 82.0, 69.9, 69.2, 29.7, 27.1, 26.9, 25.9, 24.4, 19.5, 18.3, -
5.54, -5.61; IR (NaCl/thin film): 3312, 3071, 3050, 2956, 2930, 2894, 2857, 1472, 
1463, 1428, 1390, 1361, 1258, 1193, 1159, 1110, 1103, 1039, 1028, 1006, 851, 837, 
822, 777, 741, 703 cm–1; HRMS (ESI) calc’d for C28H42O2Si2 [M+H]+ 467.2713, 
found 467.2796. 
 
 
1-((triisopropylsilyl)oxy)propan-2-one (67) 
Acetol (2.27 g, 30.6 mmol) was added to a solution of imidazole (4.38 g, 64.3 
mmol) in DMF (40 mL), followed by the addition of TIPSCl (7.21 mL, 33.7 mmol). 
After stirring at room temperature for 1.5 h, the reaction was quenched with sat. 
NH4Cl, and the aqueous layer was extracted from diethyl ether four times. The 
combined organic layers were washed with water, then brine, and finally dried over 
MgSO4. The crude product was purified by column chromatography (5%→20% 
EtOAc/Hex) to give 67 (6.72 g, 95% yield). 1H NMR (400 MHz, CDCl3) δ 4.20 (d, J 
= 1.2 Hz, 2H), 2.22 (s, 3H), 1.18 – 0.99 (m, 21H); 13C NMR (101 MHz, CDCl3) δ 
210.1, 69.9, 26.1, 17.9, 17.7, 12.3, 11.8; IR (NaCl/thin film): 3503, 2944, 2893, 2867, 
1720, 1464, 1435, 1417, 1384, 1354, 1248,1231, 1123, 1069, 1014, 996, 919, 882, 
838, 799 cm–1; HRMS (Multimode-ESI/APCI) calc’d for C12H26O2Si [M+H3O]+ 
249.1880, found 249.1871. 
Me
OH
O
Me
OTIPS
O
66 67
Chapter 2 – Efforts in Our Laboratory 47 
 
 
2-(propa-1,2-dien-1-yl)-1,3,2-dioxaborolane (68) 
A 2-neck flask was charged with Mg turnings (2.43 g, 100 mmol) and HgCl2 
(46.2 mg, 0.170 mmol) and then gently heated while flushing with N2 to remove 
excess moisture. Et2O (15 mL) was added and the reaction flask was fitted with a 
reflux condenser. Propargyl bromide (10.3 g, 86.8 mmol) in Et2O (50 mL) was added 
dropwise, and the reaction was cooled with a salt/ice bath. After stirring for 45 min at 
room temperature, the Grignard reagent was added dropwise via canula to a solution 
of trimethyl borate (9.02 g, 86.8 mmol) in Et2O (100 mL) at –78 °C over about 30 
min. The reaction was allowed to warm to room temperature, and then cooled to 0 °C 
before adding HCl (3M, 100 mL) dropwise using an addition funnel. The mixture was 
stirred at 0 °C for approximately 25 min and then allowed to warm to room 
temperature for 5 min. The aqueous layer was extracted from Et2O (50 mL x 3) and 
the combined organics were dried over MgSO4. The organic layer was filtered into a 
flame-dried 500 mL round-bottom flask, and then the solvent was reduced under 
pressure to leave ~200 mL. Ethylene glycol (8.08 g, 130 mmol) and MgSO4 (100 g) 
were added and the reaction was stirred using a mechanical stirrer at room 
temperature for 23 h. The mixture was filtered, washing with Et2O, and the solvent 
was reduced under pressure. The crude was dissolved in 150 mL pentane at 0 °C, and 
excess ethylene glycol as removed as the bottom layer if necessary. If a precipitate 
•
68
Br B O
O
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remained, the crude was filtered through oven-dried Celite. The crude product was 
purified via distillation and stored under inert gas in the fridge. 
 
 
(S)-2-methyl-1-((triisopropylsilyl)oxy)pent-4-yn-2-ol (69) 
A mixture of (S)-3,3’-Cl-BINOL (35.7 mg, 0.101 mmol) and 2-(propa-1,2-
dien-1-yl)-1,3,2-dioxaborolane (0.166 g, 1.501 mmol) was stirred at room 
temperature for 5 min. To this was added ketone 67 (0.232 g, 1.01 mmol), and the 
reaction mixture was subjected to microwave irradiation at 10 W for 1.5 h. The next 
day, the residue was purified via column chromatography (5% EtOAc/Hex) to 
provide 69 (0.188 g, 69% yield). [α]  = +2 ° (c = 0.435, CHCl3); 1H NMR (500 
MHz, CDCl3) δ 3.72 (d, J = 9.3 Hz, 1H), 3.54 (d, J = 9.3 Hz, 1H), 2.62 (s, 1H), 2.50 – 
2.37 (m, 2H), 2.01 (t, J = 2.7 Hz, 1H), 1.27 (s, 3H), 1.08 (d, J = 1.0 Hz, 12H), 1.07 
(dd, J = 2.3, 1.3 Hz, 9H); 13C NMR (126 MHz, CDCl3) δ 193.0, 81.0, 72.1, 70.4, 
69.2, 29.0, 22.9, 18.0, 12.0; IR (NaCl/thin film): 3558, 3454, 3314, 2944, 2888, 2867, 
1463, 1422, 1383, 1157, 1100, 1069, 1014, 996, 911, 882, 809, 774 cm–1. 
 
 
TBSCl (0.120 g, 0.799 mmol), imidazole (0.0544 g, 0.799 mmol) and 69 
(0.108 g, 0.399 mmol) were heated neat to 120 °C overnight. The reaction was 
quenched with water and diluted with dichloromethane, and the aqueous layer was 
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extracted from dichloromethane four times. The combined organic layers were 
washed with brine and dried over MgSO4. The crude mixture was separated using 
column chromatography (hexanes) to afford 70a (27.6 g, 18% yield, 41% yield brsm) 
and 70b (13.3 mg, 9% yield, 20% yield brsm).  
(S)-8,8-diisopropyl-2,2,3,3,5,9-hexamethyl-5-(prop-2-yn-1-yl)-4,7-dioxa-3,8-
disiladecane (70a) 
 [α]  = +3 ° (c = 0.735, CHCl3); 1H NMR (500 MHz, CDCl3) δ 3.68 – 3.44 (m, 
2H), 2.49 – 2.34 (m, 2H), 1.94 (td, J = 2.7, 1.3 Hz, 1H), 1.29 (d, J = 1.5 Hz, 3H), 1.07 
(d, J = 1.2 Hz, 15H), 1.06 – 1.04 (m, 8H), 0.86 (d, J = 1.4 Hz, 9H), 0.12 (d, J = 1.4 
Hz, 3H), 0.09 (d, J = 1.5 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 82.1, 75.5, 70.2, 
69.9, 29.9, 25.8, 24.6, 18.2, 18.0, 12.1, -2.09; IR (NaCl/thin film): 3314, 2944, 2893, 
2866, 1472, 1458, 1387, 1254, 1197, 1164, 1108, 1066, 1035, 1016, 1004, 882, 835, 
806, 774 cm–1. 
(S)-8,8-diisopropyl-2,2,3,3,6,9-hexamethyl-6-(prop-2-yn-1-yl)-4,7-dioxa-3,8-
disiladecane (70b) 
[α]  = +3 ° (c = 0.460, CHCl3); 1H NMR (500 MHz, CDCl3) δ 3.51 (dd, J = 61.1, 
9.4 Hz, 2H), 2.53 – 2.33 (m, 2H), 1.93 (t, J = 2.7 Hz, 1H), 1.28 (s, 3H), 1.05 – 1.04 
(m, 21H), 0.90 (s, 9H), 0.06 (d, J = 1.0 Hz, 6H); 13C NMR (126 MHz, CDCl3) δ 82.1, 
75.1, 69.9, 69.6, 30.0, 25.9, 24.8, 18.3, 13.5, -5.46, -5.51; IR (NaCl/thin film): 3315, 
2929, 2866, 2360, 1653, 1559, 1506, 1472, 1464, 1388, 1257, 1197, 1168, 1144, 
1103, 1044, 1006, 882, 851, 837, 776 cm–1. 
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(S)-2,2,3,3,5,8,8,9,9-nonamethyl-5-(prop-2-yn-1-yl)-4,7-dioxa-3,8-disiladecane 
(70c) 
K2CO3 (78.7 mg, 0.569 mmol), followed by Ohira–Bestmann reagent (65.6 
mg, 0.342 mmol), was added to a solution of crude aldehyde (98.7 mg, 0.285 mmol) 
in MeOH (5 mL), and this was stirred at room temperature overnight. The reaction 
was quenched with sat. NaHCO3 and diluted with Et2O. The aqueous layer was 
extracted from Et2O three times, and then the combined organic layers were washed 
with brine and dried over MgSO4. The crude product was purified by column 
chromatography (hexanes) to provide alkyne 70c (70.7 mg, 72% yield over two 
steps). 1H NMR (500 MHz, CDCl3) δ 3.51 (d, J = 9.6 Hz, 1H), 3.41 (d, J = 9.5 Hz, 
1H), 2.42 (dd, J = 16.5, 2.7 Hz, 1H), 2.32 (dd, J = 16.5, 2.7 Hz, 1H), 1.94 (t, J = 2.7 
Hz, 1H), 1.25 (s, 3H), 0.90 (s, 9H), 0.86 (s, 9H), 0.11 (s, 3H), 0.09 (s, 3H), 0.06 (s, 
6H); 13C NMR (126 MHz, CDCl3) δ 82.0, 75.4, 69.8, 69.6, 29.8, 25.9, 25.8, 24.4, 
18.3, 18.2, –2.26, –5.50; IR (NaCl/thin film): 3315, 2956, 2930, 2887, 2858, 1472, 
1464, 1388, 1362, 1310, 1255, 1197, 1165, 1137, 1104, 1043, 1007, 939, 834, 814, 
798, 775 cm–1; HRMS (ESI) calc’d for C18H38O2Si2 [M+K]+ 381.2042, found 
381.2170. 
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(3S,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-2,3,4,5,6,7,8,9,10,11,12,13,14,15-
tetradecahydro-1H-cyclopenta[a]phenanthrene-3,17-diyl diacetate (75) 
 One drop of conc. H2SO4 was added to a solution of trans-androsterone 24 
(0.643 g, 2.21 mmol) in isopropenyl acetate (16 mL) and this was heated to reflux for 
4 h. Upon cooling to room temperature, the reaction was quenched with 0.5 M 
Na2CO3 (65 mL). The aqueous layer was extracted from EtOAc (65 mL, then 35 mL) 
and the combined organics were washed with water (65 mL) and brine (65 mL), and 
then dried over MgSO4. The crude product was purified via column chromatography 
(neutral alumina powder, CH2Cl2) and then recrystallized from Et2O to give 75 (0.311 
g, 38% yield).  
 
 
(3S,5S,8R,9S,10S,13S,14S,16S)-10,13-dimethyl-17-oxohexadecahydro-1H-
cyclopenta[a]phenanthrene-3,16-diyl diacetate (76) 
 Acetic anhydride (0.32 mL, 3.35 mmol) was added to a solution off steroid 75 
(0.279 g, 0.745 mmol) and Pd(OAc)4 (0.364 g, 0.820 mmol) in acetic acid (13 mL). 
After stirring overnight at room temperature, the acetic acid was removed via rotary 
evaporation. The resulting residue was diluted in Et2O (20 mL) and water-saturated 
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Et2O (20 mL) to decompose the lead complex. The mixture was filtered, and the 
filtrant was washed with 0.5 M Na2CO3 (40 mL), water (40 mL), and brine (40 mL), 
Upon drying over MgSO4, the crude product was purified via column 
chromatography (5% EtOAC/95% CH2Cl2) to give 76 (0.151 g, 52% yield, 61% 
b.r.s.m.). 
 
 
(3S,5S,8R,9S,10S,13S,14S,16S)-3,16-bis(methoxymethoxy)-10,13-
dimethyltetradecahydro-1H-cyclopenta[a]phenanthren-17(2H)-one (76b) 
Bu4NI (35.0 mg, 0.0949 mmol), followed by N,N-diisopropylethylamine (0.33 
mL, 1.90 mmol) was added to a solution of steroid 76a (0.145 g, 0.474 mmol) in THF 
(4 mL). After dropwise addition of chloromethyl methyl ether (MOMCl, 0.18 mL, 
2.37 mmol), the reaction was heated to 50 °C and stirred overnight. Upon cooling to 
room temperature, the reaction was quenched with water and the aqueous layer was 
extracted from Et2O three times. The combined organic layers were washed with 
brine and dried over MgSO4. The crude product was purified by column 
chromatography (10%→15% EtOAc/Hex) to provide 76b (0.187 g, 80% yield). [α]
 = –72 ° (c = 0.540, CHCl3); 1H NMR (500 MHz, CDCl3) δ 4.86 (d, J = 6.7 Hz, 
1H), 4.73 (d, J = 6.7 Hz, 1H), 4.70 – 4.66 (m, 2H), 3.76 (s, 1H), 3.50 (tt, J = 11.2, 4.8 
Hz, 1H), 3.41 (s, 3H), 3.37 (s, 3H), 2.23 (ddd, J = 18.7, 7.7, 1.1 Hz, 1H), 1.96 – 1.90 
(m, 1H), 1.91 – 1.69 (m, 3H), 1.64 (ddt, J = 16.2, 8.8, 3.4 Hz, 3H), 1.59 – 1.23 (m, 
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9H), 1.18 – 1.08 (m, 1H), 1.03 – 0.88 (m, 2H), 0.84 (s, 3H), 0.81 (s, 3H); 13C NMR 
(126 MHz, CDCl3) δ 215.1, 96.4, 94.6, 89.3, 76.2, 55.5, 55.1, 54.4, 45.3, 44.9, 42.1, 
36.9, 36.8, 36.4, 35.9, 35.2, 34.5, 31.8, 28.6, 28.5, 20.5, 12.3, 12.2; IR (NaCl/thin 
film): 2931, 2849, 1753, 1464, 1449, 1382, 1218, 1146, 1104, 1040, 1009, 916 cm–1; 
HRMS (Multimode-ESI/APCI) calc’d for C23H38O5 [M+Na]+ 417.2611, found 
417.2596. 
 
 
(3S,5S,8R,9S,10S,13S,14S,16S)-3,16-bis((2-methoxyethoxy)methoxy)-10,13-
dimethyltetradecahydro-1H-cyclopenta[a]phenanthren-17(2H)-one (76c) 
Bu4NI (8.6 mg, 0.0232 mmol), followed by N,N-diisopropylethylamine (0.08 
mL, 0.463 mmol) was added to a solution of steroid 76a (35.5 mg, 0.116 mmol) in 
THF (1 mL). After dropwise addition of 2-methoxyethoxymethyl chloride (MEMCl, 
0.07 mL, 0.579 mmol), the reaction was heated to 50 °C and stirred overnight. Upon 
cooling to room temperature, the reaction was quenched with water and the aqueous 
layer was extracted from Et2O three times. The combined organic layers were washed 
with brine and dried over MgSO4. The crude product was purified by column 
chromatography (20%→35% EtOAc/Hex) to provide 76c (22.7 mg, 41% yield). IR 
(NaCl/thin film): 3365, 3166, 2930, 2863, 1731, 1451, 1417, 1384, 1298, 1226, 1169, 
1132, 1110, 1093, 1046, 930 cm–1; HRMS (Multimode-ESI/APCI) calc’d for 
C27H46O7 [M+Na]+ 505.3136, found 505.3108. 
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propa-1,2-dien-1-ylmagnesium bromide (77) 
A 2-neck flask was charged with Mg turnings (0.194 g, 7.98 mmol) and HgCl2 
(2.2 mg, 0.00798 mmol) and then gently heated while flushing with N2 to remove 
excess moisture. Et2O (2 mL) was added and the reaction flask was fitted with a 
reflux condenser. Propargyl bromide (0.949 g, 7.98 mmol) was added dropwise while 
simultaneously adding Et2O (3 mL) dropwise to maintain reflux. After stirring for 1 
h, the reagent was ready to use as is. 
 
 
(3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-hydroxy-10,13-dimethyl-17-(prop-2-yn-1-
yl)hexadecahydro-1H-cyclopenta[a]phenanthrene-3,16-diyl diacetate (78) 
Allenylmagnesium bromide 77 (0.0259 mmol, 0.02 mL of 1.68 M soln. in 
Et2O) was added to a solution of steroid 76 (10.1 mg, 0.0259 mmol) in THF (2 mL) at 
–78 °C. After 1.5 h, another 0.02 mL (0.0259 mmol, 1 equiv) of allenylmagnesium 
bromide was added, and this was repeated every 30 min until a total of 4 equiv of 
allenylmagnesium bromide had been added. After a total of 3.5 h, the reaction was 
quenched with water, and the aqueous layer was extracted from Et2O three times. The 
combined organic layers were washed with brine and dried over MgSO4, which 
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provided pure 78 (8.7 mg, 78% yield) without further purification. 1H NMR (500 
MHz, CDCl3) δ 5.01 (dd, J = 8.3, 5.8 Hz, 1H), 4.68 (tt, J = 11.4, 4.9 Hz, 1H), 2.61 – 
2.49 (m, 2H), 2.41 – 2.26 (m, 2H), 2.10 (s, 3H), 2.02 (s, 3H), 1.86 – 1.78 (m, 1H), 
1.73 (dt, J = 13.2, 3.6 Hz, 1H), 1.68 – 1.43 (m, 6H), 1.41 – 1.11 (m, 8H), 1.11 – 0.93 
(m, 2H), 0.91 (s, 3H), 0.87 (dd, J = 12.2, 4.5 Hz, 1H), 0.84 (s, 3H), 0.65 (td, J = 11.5, 
3.9 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 170.6, 169.9, 110.0, 80.7, 80.6, 73.5, 
71.2, 54.3, 47.2, 46.0, 44.7, 36.8, 35.8, 35.7, 34.0, 33.2, 32.3, 31.8, 28.4, 27.5, 27.2, 
21.4, 21.1, 20.7, 13.8, 12.2; IR (NaCl/thin film): 3305, 3270, 2930, 2853, 1730, 1449, 
1377, 1362, 1244, 1155, 1041, 1025 cm–1; HRMS (Multimode-ESI/APCI) calc’d for 
C26H38O5 [M–OH]+ 413.2692, found 413.2692. 
 
 
(3S,5S,8R,9S,10S,13S,14S,16S,17R)-3,16-bis(methoxymethoxy)-10,13-dimethyl-17-
(prop-2-yn-1-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-17-ol (78b) 
Allenylmagnesium bromide 77 (0.0467 mmol, 0.03 mL of 1.63 M soln. in 
Et2O) was added to a solution of steroid 76b (9.2 mg, 0.0233 mmol) in toluene (0.5 
mL) at –78 °C. After 30 min, another 0.03 mL of allenylmagnesium bromide was 
added. After a total of 1 h, the reaction was quenched with water, and the aqueous 
layer was extracted from Et2O three times. The combined organic layers were washed 
with brine and dried over MgSO4, which provided pure 78b (7.3 mg, 72% yield) 
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without further purification. [α]  = –20 ° (c = 0.405, CHCl3); 1H NMR (500 MHz, 
CDCl3) δ 4.76 – 4.72 (m, 2H), 4.69 – 4.65 (m, 2H), 3.48 (tt, J = 11.1, 4.8 Hz, 1H), 
3.42 (s, 3H), 3.36 (s, 3H), 3.28 (s, 1H), 3.19 – 3.16 (m, 1H), 2.46 – 2.34 (m, 2H), 2.02 
– 1.95 (m, 2H), 1.83 (tdd, J = 12.4, 6.3, 3.4 Hz, 2H), 1.74 – 1.50 (m, 5H), 1.49 – 1.38 
(m, 2H), 1.37 – 1.15 (m, 5H), 1.08 (ddt, J = 12.2, 8.7, 3.2 Hz, 1H), 1.03 – 0.90 (m, 
2H), 0.89 (s, 3H), 0.88 – 0.82 (m, 1H), 0.81 (s, 3H), 0.65 (ddd, J = 12.3, 10.5, 4.2 Hz, 
1H); 13C NMR (126 MHz, CDCl3) δ 97.7, 94.6, 90.3, 81.4, 76.4, 76.3, 69.5, 56.0, 
55.1, 54.6, 48.0, 45.0, 43.8, 39.4, 37.8, 37.0, 35.8, 35.32, 34.8, 32.6, 31.7, 28.7, 28.6, 
20.5, 12.4, 12.3; IR (NaCl/thin film): 3528, 3305, 3275, 2931, 2849, 1469, 1449, 
1379, 1300, 1215, 1177, 1151, 1103, 1043, 1035, 1009, 927, 917 cm–1; HRMS 
(Multimode-ESI/APCI) calc’d for C26H42O5 [M+H]+ 435.3105, found 435.3078. 
 
 
(3S,5S,8R,9S,10S,13S,14S,16S,17R)-3,16-bis((2-methoxyethoxy)methoxy)-10,13-
dimethyl-17-(prop-2-yn-1-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-17-ol 
(78c) 
Allenylmagnesium bromide 77 (0.0783 mmol, 0.05 mL of 1.62 M soln. in 
Et2O) was added to a solution of steroid 76c (12.6 mg, 0.0261 mmol) in THF (0.5 
mL) at –78 °C. After 30 min, another 0.03 mL (0.0522 mmol) of allenylmagnesium 
bromide was added. After a total of 45 min, the reaction was quenched with water, 
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and the aqueous layer was extracted from Et2O three times. The combined organic 
layers were washed with brine and dried over MgSO4, which provided pure 78c (8.6 
mg, 63% yield) without further purification. [α]  = –18 ° (c = 0.500, CHCl3); 1H 
NMR (500 MHz, CDCl3) δ 4.87 – 4.80 (m, 2H), 4.78 – 4.74 (m, 2H), 3.77 – 3.74 (m, 
2H), 3.72 – 3.68 (m, 2H), 3.58 – 3.54 (m, 4H), 3.54 – 3.48 (m, 1H), 3.39 (s, 6H), 3.29 
(s, 1H), 3.25 (s, 1H), 2.42 (qd, J = 16.4, 2.6 Hz, 2H), 2.00 (dd, J = 13.0, 6.7 Hz, 1H), 
1.95 (t, J = 2.6 Hz, 1H), 1.87 – 1.76 (m, 2H), 1.73 – 1.48 (m, 5H), 1.47 – 1.36 (m, 
2H), 1.36 – 1.13 (m, 6H), 1.12 – 1.03 (m, 1H), 1.02 – 0.90 (m, 2H), 0.87 (s, 3H), 0.80 
(s, 3H), 0.65 (ddd, J = 12.3, 10.5, 4.2 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 96.8, 
93.6, 90.8, 81.5, 76.4, 76.3, 71.9, 71.7, 69.5, 67.9, 66.7, 59.0, 59.0, 54.6, 47.9, 44.9, 
43.9, 39.4, 37.8, 37.0, 35.8, 35.2, 34.8, 32.5, 31.7, 28.7, 28.6, 20.5, 12.4, 12.3; IR 
(NaCl/thin film): 3480, 3305, 3262, 2929, 2849, 1466, 1450, 1378, 1367, 1200, 1170, 
1130, 1111, 1090, 1047, 984, 930, 849 cm–1; HRMS (Multimode-ESI/APCI) calc’d 
for C30H50O7 [M+Na]+ 545.3449, found 545.3474. 
 
 
(3S,5S,8R,9S,10S,13S,14S,16S)-16-bromo-3-hydroxy-10,13-
dimethyltetradecahydro-1H-cyclopenta[a]phenanthren-17(2H)-one (79) 
 CuBr2 (1.16 g, 5.21 mmol) was added to a solution of trans-androsterone 24 
(0.505 g, 1.74 mmol) in distilled methanol (20 mL) and this was heated to reflux and 
stirred overnight. The next day, the reaction was quenched with water, and the 
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aqueous layer was extracted from chloroform three times. The combined organic 
layers were washed with brine and dried over MgSO4. The crude bromide 79 was 
used in the following step without any further purification.  
 
 
(3S,5S,8R,9S,10S,13S,14S,16R)-3,16-dihydroxy-10,13-dimethyltetradecahydro-1H-
cyclopenta[a]phenanthren-17(2H)-one (80) 
 Bromide 79 (0.642 g, 1.74 mmol) was dissolved in 75% aq. DMF (30 mL), 
and then NaOH (0.0834 g, 2.08 mmol) was added. After 30 min, the reaction was 
poured into 1% HCl solution and the aqueous was extracted from EtOAc. The organic 
layer was washed with 5% NaHCO3, then water, and then dried over MgSO4. The 
crude diol 80 (0.400 g, 75% yield two steps) was clean enough that purification was 
unnecessary. 
 
 
(3S,5S,8R,9S,10S,13S,14S,16R)-3,16-bis((tert-butyldimethylsilyl)oxy)-10,13-
dimethyltetradecahydro-1H-cyclopenta[a]phenanthren-17(2H)-one (81) 
Imidazole (0.206 g, 3.03 mmol), followed by TBSCl (0.400 g, 2.65 mmol), 
was added to a solution of 80 (0.387 g, 1.26 mmol) in dichloromethane (10 mL). The 
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reaction was heated to 50 °C overnight and then quenched water and diluted with 
dichloromethane. The aqueous layer was extracted from dichloromethane three times, 
and then the combined organics were washed with brine and dried over MgSO4. The 
crude product was purified by column chromatography (hexanes) to give 81 (0.539 g, 
80% yield). [α]  = +9 ° (c = 0.740, CHCl3); 1H NMR (500 MHz, CDCl3) δ 4.31 (d, 
J = 8.1 Hz, 1H), 3.54 (dd, J = 11.3, 6.5 Hz, 1H), 1.95 – 1.02 (m, 20H), 0.94 (d, J = 
8.1 Hz, 2H), 0.92 (s, 1H), 0.89 (d, J = 4.9 Hz, 15H), 0.81 (s, 1H), 0.77 (d, J = 2.1 Hz, 
1H), 0.28 – 0.19 (m, 1H), 0.11 (s, 3H), 0.10 (s, 3H), 0.05 (s, 9H); 13C NMR (126 
MHz, CDCl3) δ 179.6, 72.3, 72.0, 54.5, 48.4, 47.4, 45.1, 38.7, 37.1, 35.7, 35.6, 35.0, 
32.8, 31.9, 30.7, 28.5, 25.9, 25.8, 25.7, 25.6, 25.6, 20.2, 14.6, 12.3, -4.53; IR 
(NaCl/thin film): 2929, 2856, 1754, 1723, 1711, 1693, 1470, 1461, 1454, 1446, 1385, 
1360, 1253, 1179, 1150, 1095, 1071, 1004, 870,835, 776 cm–1. 
 
 
(3S,5S,8R,9S,10S,13S,14S,16R)-3,16-bis(methoxymethoxy)-10,13-
dimethyltetradecahydro-1H-cyclopenta[a]phenanthren-17(2H)-one (84) 
Bu4NI (14.6 mg, 0.0396 mmol), followed by N,N-diisopropylethylamine (0.14 
mL, 0.792 mmol) was added to a solution of steroid 80 (60.7 mg, 0.198 mmol) in 
THF (1.6 mL). After dropwise addition of chloromethyl methyl ether (MOMCl, 0.08 
mL, 0.990 mmol), the reaction was heated to 50 °C and stirred overnight. Upon 
cooling to room temperature, the reaction was quenched with water and the aqueous 
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layer was extracted from Et2O three times. The combined organic layers were washed 
with brine and dried over MgSO4. The crude product was purified by column 
chromatography (20% EtOAc/Hex) to provide 84 (76.4 mg, 98% yield). [α]  = +86 
° (c = 0.255, CHCl3); 1H NMR (500 MHz, CDCl3) δ 4.87 (d, J = 6.7 Hz, 1H), 4.70 – 
4.65 (m, 3H), 4.32 (dd, J = 7.1, 2.5 Hz, 1H), 3.49 (tt, J = 11.2, 4.8 Hz, 1H), 3.40 (s, 
3H), 3.36 (s, 3H), 1.92 – 1.68 (m, 5H), 1.68 – 1.60 (m, 2H), 1.59 – 1.38 (m, 4H), 1.38 
– 1.23 (m, 5H), 1.11 (ddt, J = 15.7, 12.5, 3.4 Hz, 1H), 1.04 – 0.92 (m, 2H), 0.90 (s, 
3H), 0.83 (s, 3H), 0.70 (ddd, J = 13.7, 7.5, 4.1 Hz, 1H); 13C NMR (126 MHz, CDCl3) 
δ 217.3, 96.1, 94.6, 76.2, 74.4, 55.6, 55.1, 54.4, 48.8, 47.7, 44.9, 36.9, 35.8, 35.3, 
35.0, 31.6, 30.7, 29.7, 28.7, 28.4, 20.2, 14.4, 12.2; IR (NaCl/thin film): 2930, 2856, 
1751, 1464, 1449, 1375, 1215, 1146, 1102, 1066, 1043, 1012, 917 cm–1; HRMS 
(Multimode-ESI/APCI) calc’d for C23H38O5 [M+H]+ 395.2792, found 395.2767. 
 
 
(3S,5S,8R,9S,10S,13S,14S,16R,17S)-3,16-bis(methoxymethoxy)-10,13-dimethyl-17-
(prop-2-yn-1-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-17-ol (85) 
TiCl4 (0.01 mL, 0.0471 mmol) was added to a solution of steroid 84 (9.3 mg, 
0.0236 mmol) in THF (0.5 mL) at –78 °C, followed by the addition of 
allenylmagnesium bromide 77 (0.0707 mmol, 0.04 mL of 1.63 M soln. in Et2O). 
After 30 min, the reaction was quenched with water and diluted with Et2O, and the 
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aqueous layer was extracted from Et2O three times. The combined organic layers 
were washed with brine and dried over MgSO4 to give pure 85 (7.9 mg, 77% yield) 
without further purification. [α]  = –30 ° (c = 0.455, CHCl3); 1H NMR (500 MHz, 
CDCl3) δ 4.72 (q, J = 6.8 Hz, 2H), 4.67 (d, J = 1.2 Hz, 2H), 4.03 (dd, J = 8.0, 3.1 Hz, 
1H), 3.48 (tt, J = 11.2, 4.7 Hz, 1H), 3.40 (s, 3H), 3.36 (s, 3H), 3.21 (s, 1H), 2.49 – 
2.39 (m, 2H), 1.87 – 1.80 (m, 1H), 1.97 (t, J = 2.7 Hz, 1H), 1.92 (td, J = 11.4, 9.0 Hz, 
2H), 1.78 – 1.68 (m, 2H), 1.65 – 1.53 (m, 8H), 1.48 – 1.38 (m, 2H), 1.36 – 1.19 (m, 
7H), 1.13 – 1.05 (m, 2H), 1.00 – 0.82 (m, 3H), 0.80 (s, 3H), 0.72 (s, 3H); 13C NMR 
(126 MHz, CDCl3) δ 96.5, 94.6, 81.6, 81.5, 80.2, 76.3, 70.2, 56.0, 55.1, 54.1, 48.4, 
47.2, 45.0, 37.0, 35.7, 35.4, 35.3, 32.4, 32.1, 30.5, 28.8, 28.7, 25.8, 20.2, 15.5, 12.3; 
IR (NaCl/thin film): 3478, 3311, 3264, 2941, 2923, 2898, 2848, 1468, 1450, 1384, 
1353, 1219, 1150, 1104, 1076, 1040, 1026, 1013, 989, 960, 916 cm–1; HRMS 
(Multimode-ESI/APCI) calc’d for C26H42O5 [M+Na]+ 457.2924, found 457.2914. 
 
 
buta-1,2-dien-1-ylmagnesium bromide (86) 
86 was prepared from 3-bromobut-1-yne using the same procedure as 
allenylmagnesium bromide 77. 
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TiCl4 (0.01 mL, 0.0542 mmol) was added to a solution of steroid 84 (10.7 mg, 
0.0271 mmol) in THF (0.5 mL) at –78 °C, followed by the addition of buta-1,2-
dienyl-magnesium bromide 86 (0.0814 mmol, 0.05 mL of 1.50 M soln. in Et2O). 
After 30 min, the reaction was quenched with water and diluted with Et2O, and the 
aqueous layer was extracted from Et2O three times. The combined organic layers 
were washed with brine and dried over MgSO4 to give a mixture of 87 and 88. The 
two products were separated by column chromatography (15% EtOAc/Hex) to afford 
87 (5.7 mg, 47% yield) and 88 (2.8 mg, 23% yield).  
(3S,5S,8R,9S,10S,13S,14S,16R,17S)-17-((S)-but-3-yn-2-yl)-3,16-
bis(methoxymethoxy)-10,13-dimethylhexadecahydro-1H-
cyclopenta[a]phenanthren-17-ol (87) 
[α]  = +5 ° (c = 0.240, CHCl3); 1H NMR (500 MHz, CDCl3) δ 4.83 (d, J = 6.7 Hz, 
1H), 4.71 – 4.65 (m, 3H), 3.96 (dd, J = 7.6, 2.5 Hz, 1H), 3.49 (tt, J = 11.2, 4.8 Hz, 
1H), 3.41 (s, 3H), 3.36 (s, 3H), 3.21 (s, 1H), 2.73 (qd, J = 6.9, 2.5 Hz, 1H), 2.01 (d, J 
= 2.4 Hz, 1H), 1.91 – 1.76 (m, 3H), 1.70 (dt, J = 13.3, 3.6 Hz, 1H), 1.59 (tddd, J = 
20.4, 12.4, 9.0, 5.5 Hz, 7H), 1.48 – 1.37 (m, 1H), 1.36 – 1.29 (m, 2H), 1.28 (d, J = 6.9 
Me
Me
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Hz, 3H), 1.25 (t, J = 1.3 Hz, 2H), 1.12 – 1.04 (m, 1H), 0.95 (tdd, J = 13.0, 8.3, 4.6 
Hz, 2H), 0.79 (s, 3H), 0.75 (s, 3H), 0.69 (ddd, J = 12.5, 10.4, 3.7 Hz, 1H); 13C NMR 
(126 MHz, CDCl3) δ 97.9, 94.6, 87.6, 83.2, 82.1, 76.3, 69.5, 56.3, 55.1, 53.8, 49.0, 
47.4, 44.9, 37.0, 35.6, 35.3, 35.3, 33.7, 33.3, 32.1, 32.0, 28.7, 28.7, 20.5, 16.7, 15.0, 
12.2; IR (NaCl/thin film): 3520, 3306, 3270, 2928, 2849, 1461, 1450, 1383, 1352, 
1340, 1296, 1218, 1151, 1104, 1070, 1044, 989, 917 cm–1. 
 (3S,5S,8R,9S,10S,13S,14S,16R,17S)-17-((R)-but-3-yn-2-yl)-3,16-
bis(methoxymethoxy)-10,13-dimethylhexadecahydro-1H-
cyclopenta[a]phenanthren-17-ol (88) 
[α]  = –24 ° (c = 0.125, CHCl3); 1H NMR (500 MHz, CDCl3) δ 4.75 (d, J = 6.8 Hz, 
1H), 4.70 – 4.64 (m, 3H), 4.01 (dd, J = 8.1, 2.0 Hz, 1H), 3.49 (tt, J = 11.2, 4.7 Hz, 
1H), 3.40 (s, 3H), 3.36 (s, 3H), 3.13 (s, 1H), 2.68 (qd, J = 7.0, 2.5 Hz, 1H), 2.11 (d, J 
= 2.5 Hz, 1H), 2.06 – 2.00 (m, 1H), 1.91 – 1.68 (m, 5H), 1.68 – 1.02 (m, 12H), 1.01 – 
0.85 (m, 3H), 0.84 (s, 3H), 0.81 (d, J = 0.6 Hz, 3H), 0.74 – 0.65 (m, 1H); 13C NMR 
(126 MHz, CDCl3) δ 96.1, 94.6, 87.0, 82.3, 80.8, 76.4, 70.7, 56.6, 55.1, 53.9, 49.0, 
45.0, 37.0, 35.7, 35.3, 35.3, 32.5, 32.1, 31.9, 31.7, 29.7, 28.8, 28.8, 20.4, 16.3, 15.1, 
12.2; IR (NaCl/thin film): 3538, 3231, 2930, 2848, 2819, 1459, 1449, 1377, 1355, 
1261, 1219, 1150, 1135, 1103, 1041, 987, 917, 908, 796 cm–1. 
 
 
(S)-but-3-yn-2-yl methanesulfonate (91) 
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 Et3N (0.09 mL, 0.673 mmol) was added to a solution of alcohol 89 (23.6 mg, 
0.337 mmol) in dichloromethane (1.7 mL) at –78 °C, followed by the addition of 
mesyl chloride (0.04 mL, 0.505 mmol). After 1.25 h at –78 °C, the reaction was 
quenched with sat. NaHCO3 and allowed to warm to room temperature. The organic 
layer was separated, washed with brine, and concentrated. The resulting reside was 
diluted with ether, which was washed twice with water, and then once with brine. The 
combined aqueous layers were washed with ether twice. The combined organic layers 
were then dried over MgSO4. The crude mesylate 91 (34.3 mg, 69% yield) was used 
without further purification. 
 
 
(3S,5S,8R,9S,10S,13S,14S,16R,17S)-17-((S)-but-3-yn-2-yl)-3,16-
bis(methoxymethoxy)-10,13-dimethylhexadecahydro-1H-
cyclopenta[a]phenanthren-17-ol (87) 
 Triphenyl phosphine (3.5 mg, 0.0134 mmol), followed by mesylate 91 (0.119 
g, 0.804 mmol), was added to a solution of Pd(OAc)2 (9.0 mg, 0.0134 mmol) in THF 
(0.9 mL) at –78 °C. In a separate flask with stir bar, TiCl4 (0.07 mL, 0.536 mmol) 
was added to a solution of steroid 84 (0.106 g, 0.268 mmol) in THF (0.9 mL) at –78 
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°C. After stirring for 5 min, the steroid solution was added dropwise to the mesylate 
solution at –78 °C. Following the dropwise addition of Et2Zn (1.6 mL, 1.0 M in 
hexanes, 1.61 mmol), the reaction was warmed to –20 °C and stirred overnight. The 
reaction was quenched at –20 °C with 10% HCl (caution: evolution of gaseous 
ethane), and then diluted with ether and warmed to room temperature. Aqueous was 
extracted from ether twice, and the combined organics were washed with brine and 
dried over MgSO4. The crude product was purified via flash chromatography (15% 
EtOAc/Hex) to afford alcohol 87 (18.1 mg, 15% yield, 22% b.r.s.m.). See above for 
characterization data. 
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Figure 4. X-ray structure of alcohol 87. 
!
!
  Table 1.  Crystal data and structure refinement for a14213. 
Identification code  a14213 
Empirical formula  C27H44O5 
Formula weight  448.62 
Temperature  100 K 
Wavelength  0.71073 Å 
Crystal system  Tetragonal 
Space group  P 41 21 2 
Unit cell dimensions a = 12.1458(4) Å a= 90° 
 b = 12.1458(4) Å b= 90° 
 c = 34.4196(16) Å g = 90° 
Volume 5077.6(4) Å3 
Z 8 
Density (calculated) 1.174 Mg/m3 
Absorption coefficient 0.079 mm-1 
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F(000) 1968 
Crystal size 0.53 x 0.40 x 0.19 mm3 
Theta range for data collection 1.778 to 37.056°. 
Index ranges -20<=h<=20, -20<=k<=19, -58<=l<=57 
Reflections collected 233885 
Independent reflections 12739 [R(int) = 0.0650] 
Completeness to theta = 25.000° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.0000 and 0.9201 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 12739 / 0 / 409 
Goodness-of-fit on F2 1.059 
Final R indices [I>2sigma(I)] R1 = 0.0384, wR2 = 0.1003 
R indices (all data) R1 = 0.0461, wR2 = 0.1047 
Absolute structure parameter -0.12(14) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.375 and -0.224 e.Å-3 
 
 
 Table 2.  Atomic coordinates  ( x 105) and equivalent  isotropic displacement parameters (Å2x 104) 
for a14213.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
O(1) 129946(8) 149003(7) 56096(2) 195(2) 
O(2) 135140(9) 157278(8) 50225(3) 265(2) 
O(3) 90398(7) 75451(7) 53158(2) 162(1) 
O(4) 68988(6) 79928(7) 53810(2) 163(1) 
O(5) 51853(8) 86741(11) 55854(3) 329(2) 
C(1) 95261(8) 107761(8) 57862(3) 131(2) 
C(2) 89567(9) 117708(9) 56012(3) 173(2) 
C(3) 95505(9) 128430(8) 56965(3) 169(2) 
C(4) 107604(9) 127728(8) 55763(3) 138(2) 
C(5) 113396(9) 138808(8) 56244(3) 164(2) 
C(6) 125280(9) 138611(8) 54868(3) 156(2) 
C(7) 131681(9) 128993(9) 56614(3) 159(2) 
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C(8) 125595(8) 117994(8) 56125(3) 143(2) 
C(9) 113794(8) 118157(8) 57802(3) 121(1) 
C(10) 107635(8) 107272(8) 56784(3) 122(1) 
C(11) 113061(8) 96825(8) 58470(3) 143(2) 
C(12) 106897(8) 86081(8) 57478(3) 142(2) 
C(13) 94677(8) 86716(8) 58659(3) 125(1) 
C(14) 86905(8) 77591(8) 57015(3) 134(2) 
C(15) 75328(8) 83374(9) 57110(3) 145(2) 
C(16) 77380(8) 95900(9) 57160(3) 168(2) 
C(17) 89837(8) 96998(8) 56619(3) 134(2) 
C(18) 138626(10) 152948(10) 53821(3) 197(2) 
C(19) 127984(18) 166497(16) 50724(7) 479(5) 
C(20) 114429(9) 119834(9) 62240(3) 158(2) 
C(21) 93401(9) 87327(9) 63099(3) 161(2) 
C(22) 86402(9) 66577(9) 59331(3) 166(2) 
C(23) 97569(11) 60829(10) 59779(4) 242(2) 
C(24) 78585(11) 59023(9) 57405(3) 206(2) 
C(25) 72478(12) 52766(11) 55777(4) 257(2) 
C(26) 57925(10) 77554(12) 54678(3) 239(2) 
C(27) 49571(14) 94156(19) 52751(6) 400(4) 
!
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